

Recommendation: Buy
Target Price: C\$5.60

Orocobre Limited (ORL-TSX & ORE-ASX)

Raising Outlook As Brine Inventory Improves

Current Price	C\$3.66	Shares Outstanding (MM)	
52 Wk High	C\$5.04	Basic	209.2
52 Wk Low	C\$2.73	Diluted	211.4
Cash (MM)	\$52	Mngt. & Dir.	24.8
Total Debt (MM)	\$0	Market Cap.	C\$766
NAVPS	C\$3.31	Float	C\$675
Price/NAV	1.10x	EV	\$567

Fiscal YE Jun. 30		2017A	2018E	2019E
Lithium Carbonate (tonnes)	Q1	3,013	3,122	
	Q2	3,529	3,673	
100% Basis	Q3	2,784	3,765	
	Q4	2,536	3,443	
	FY	11,862	14,003 ↓	16,737

Realized Price (\$/t LCE)	\$10,678	\$11,000	\$12,000
Net Cash Cost (\$/t LCE)	\$3,738	\$3,338	\$3,300
EBITDA (% Olaroz) (MM \$)		\$65.4	\$92.8
EV/EBITDA		8.98	6.26
- adjusted EBITDA for cash corporate Admin expense			

Unless otherwise denoted, all figures shown in US\$

Investment Thesis:


Orocobre is a lithium producer in the final stages of ramping up its low-cost Olaroz brine project in Argentina. Prior to the announcement of the issues with pond management at Olaroz, we expected that rising average pricing and declining cash operating costs would support a higher stock price as the ramp up takes hold. As confidence with inventory management increases, however, we expect investors to put more value on the expansion in Argentina and a hydroxide plant in Japan, which could be drivers of the stock. Trading at less than half the multiples of the major lithium producers on a full production basis, we have a Buy recommendation on ORL.

Highlights:

- Harvest Pond Inventory Rises**
 ORL indicated that the total inventory of lithium in its ponds rose to 44,000 t LCE up from 38,300 t in July. Although we have yet to understand fully the recovery of this inventory, the changes to the pond management appear to be progressing more positively.
- Guidance Implies Modest Improvements In 2018**
 With confidence in the pond management improving, ORL indicated that production should exceed 14,000 t LCE in F2018.
- Raising Target To C\$5.60, Upgrading To Buy Recommendation**
 The improvement in operations has taken some of the risk out of the expectations for 2018 and beyond. With demand and pricing for lithium remaining high, there is a strong backdrop for ORL to expand production. Although ORL is not the lowest cost or highest quality producer of lithium, it is trading at a low multiple relative to the majors. As a result, we have raised our target to C\$5.60 from C\$4.10 and upgraded our rating to Buy from Market Perform.

Company Description:

Orocobre Limited is a Brisbane-based mining company listed on the Australian and Toronto Stock Exchanges. The company owns 66.5% of a lithium production facility with a nameplate capacity of 17,500 tpa at the Salar de Olaroz in Jujuy province of Argentina, produces boric acid at a plant in Campo Quijano and refined borates at Tincalayu.




Source: BigCharts.com, September 5, 2017 (Chart C\$)

Investors reacted positively to the latest inventory update provided last week with year-end results. While the update was not completely transparent, as the model provided focuses on the harvest ponds, Management's total inventory estimate rose 15% from the lows in July. This has provided Management with more confidence in its outlook, which includes guidance of 14,000 t LCE production for F2018. For now, this appears likely to increase investor confidence. We are raising our target to C\$5.60 from C\$4.10 and upgraded our recommendation to Buy from Market Perform. As ORL trades at less than half the multiple of majors on an EV/EBITDA basis pro forma its share of the Olaroz facility, we believe it warrants a Buy recommendation notwithstanding the production issues, lower pricing and higher costs of production.

Brine Inventory Provides Improved Outlook For Now: In the F2017 year-end results reviewed last week, ORL's operating results took a backseat to issues regarding the brine inventory, which has been the major concern over the past six months. As we noted in late July, the brine inventory fell to a new low, reaching 38,300 t LCE, down from 39,000 t at the end of March and 40,300 t LCE at the end of December. This is now reversing.

Figure 1: Harvest Pond Inventory



Source: Orocobre Ltd

Brine Inventory Rises: As shown in the figure above, which provides the latest comparison of the brine inventory model with the actual brine measurements, brine inventory has improved off a base in early July. Although the figure provided by Management does not include the actual inventory levels in the harvest ponds, ORL indicated that the total inventory of lithium in all the ponds stands at 44,000 t LCE up 15% from the low point in July.

Actuals Tracking Model: Furthermore, the actual measurements of brine inventory appear to be tracking closely with Management's model of the inventory. Recall that work since discovering the operational issues focused on increasing the area subject to solar evaporation, installing additional pumps used to effect brine volume transfer between ponds, and introducing the new operational positions and procedures.

Early Days But Must Admit The Results Are Encouraging: As it is early days in the recovery of the inventory, there are still questions around the amount of lithium in the initial and intermediate ponds, as well as the final recoverability of the lithium that may actually now be in the ponds. As a result, although we remain cautious, we must admit the new data is at the very least interesting and should start to rebuild investor confidence.

Brief Summary Of Q4/F17 Results: For completeness, as we outlined in our note on July 21, financial results for the quarter were mixed:

- Production of lithium carbonate totaled 2,536 t LCE down from 2,784 t in the March quarter, in line with Management's revised guidance.
- Sales of 2,566 t LCE were down 18% from 3,142 t in Q3/F17, as challenging winter weather had an impact.
- Realized pricing rose 5% to \$10,696/t from \$10,211/t in March, with repricing of short-term contracts at higher levels, bringing as positive impact.
- The cost of production, however, rose to \$4,279/t from \$3,565/t in the previous quarter, as lower production volumes and lower brine concentrations resulted in reagent costs impacting the results.

Guidance For Next Year Sees Modest Improvements: In July, Management delayed providing guidance, awaiting results from the pond inventory measurements. As part of the year-end review last week, ORL provided expectations for F2018.

- Production of lithium carbonate to be 14,000 t LCE up from 11,862 t in F2017
- 45% H1/F18 and 55% H2/F18
- Mix: 1/3rd volume to be battery grade and 2/3rd technical grade
- No cost guidance was provided
- Pricing is expected to rise as contracts roll off and are repriced to reflect stronger market prices

Raising Target To C\$5.60, Upgrading To Buy Recommendation: Although we remained cautious on the progress on the rebalancing, the latest results are encouraging and suggest that there is a good chance Management has put the issue of pond management behind them. Clearly it is not risk-free at this point as we have not seen the full inventory picture through all ponds nor have we seen a full year of operating with the new operating procedures in place. However, it is important to note that the lithium price remains high, demand is strong, and Orocobre is increasing its outlook. As a result, we have shifted our outlook to factor in the stronger outlook for production and pricing in F2018.

Target Goes To C\$5.60 From C\$4.10: We are using 8.1x EV/EBITDA less the \$145 MM debt balance for ORL's 66.5% of Olaroz to arrive at a value of C\$2.95 per share for ORL's operating assets. (Note that this uses our long-term pricing assumption of \$9,500/t LCE and costs of \$3,000/t.) Our C\$5.60 target arises from adding to the operating assets 80% of the NAV per share of C\$3.31 for the development assets as shown in the figure below. Our NAV includes Phase 2 expansion of Olaroz as well as the Cauchari project and the investment in Advantage Lithium. Previously we valued ORL purely on a NAV basis, which gave rise to a NAVPS of C\$5.13, providing a target of C\$4.10 at 80% of NAV.

With more than 50% return to our target, we are upgrading our recommendation to Buy from Market Perform. We note that there is still considerable risk to achieving our estimates because of the crucial improvement to the pond operation that is still being proven out.

Figure 2: NAV Valuation

Development Assets	Ownership	Discount Rate	\$MM	\$/Share
Salar de Olaroz				
Salar de Olaroz Phase 2	66.5%	11.0%	\$273	\$1.30
Borax Argentina SA	100%	8.0%	\$120	\$0.57
Cauchari	25.0%	15.0%	\$48	\$0.23
Advantage Lithium	35%		\$28	\$0.13
Total Mining Assets			\$469	\$2.24
Cash and Cash Equivalents			\$52	\$0.25
Debt				\$-
Total Financial Assets			\$52	\$0.25
Net Asset Value For Development Assets (US\$)			\$520	\$2.49
Net Asset Value For Development Assets (C\$)			\$694	C\$3.31

Source: Cormark Securities Inc.


I, MacMurray D. Whale, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject company(ies) and its (their) securities. I also certify that I have not been, and will not be receiving direct or indirect compensation in exchange for expressing the specific recommendation(s) in this report.

Orocobre Limited

Updated September 05, 2017

Price Chart and Disclosure Statement

*Information updated monthly on or about the 5th of each month.



*Cormark has this percentage of its universe assigned as the following:		*Over the past 24 months, the following percentage of issuers whose securities received a "Top Pick" or "Buy", a "Market Perform", or a "Reduce" rating from Cormark Securities Inc., have engaged Cormark to provide investment-banking services during this period.	
<i>Buy or Top Pick</i>	66%	<i>Buy or Top Pick</i>	50%
<i>Market Perform</i>	16%	<i>Market Perform</i>	27%
<i>Reduce</i>	1%	<i>Reduce</i>	33%
<i>Not Rated</i>	17%		

Recommendation / Target Chg	Date	C\$
	28-Apr-17	4.10 (MP)
	03-Feb-17	4.00 (MP)
	19-Jan-17	5.30 (B)
	19-Jan-17	5.30 (Chng Cover)
	04-Nov-16	- (U.R.)
	20-Jul-16	5.00 (MP)
	31-May-16	5.25 (B)
	23-Mar-16	4.00 (B)
	23-Mar-16	4.00 (Chng Cover)

During the last 24 months, has Cormark provided financial advice to and/or, either on its own or as a syndicate member, participated in a public offering, or private placement of securities of this issuer? Yes No

During the last 24 months, has Cormark received or is expected to receive compensation for having provided investment banking services to this issuer? Yes No

During the last 24 months, has the analyst of this company received compensation from a pool that included investment banking revenue from this issuer earned by Cormark or entities affiliated with it? Yes No

Does the analyst, associate or any individual responsible for the preparation of this research, or a member of that person's household, have a financial interest in the securities of this company? Yes No

If YES

1) Is it a long and/or short position?

2) What type of security is it?

*Does Cormark and / or one or more entities affiliated with Cormark beneficially own common shares (or any other class of common equity securities) of this company which constitutes more than 1% of the presently issued and outstanding shares of this company? Yes No

If the material operations of this issuer were viewed in the past 12 months, were any travel expenses paid or reimbursed by the issuer? N/A Yes No

Does the analyst or Cormark and / or one or more entities affiliated with Cormark have any other material conflict of interest with the issuer? Yes No

Has any partner, director, officer or employee of Cormark or any analyst involved in the preparation of this report provided services to the issuer (including acting as Officer, Director or employee of the issuer or providing advisory services to the issuer), with or without remuneration, other than normal course investment advisory or trade execution services. Yes No

If YES, name of person(s) who provided services:

The Investment Industry Regulatory Organization of Canada Rule 3400 and the Financial Industry Regulatory Authority Rule 2711 (US) require certain disclosure and compliance in research reports in general, Cormark Securities Inc. and Cormark Securities (USA) Limited (collectively "Cormark") are in compliance with the above-noted recommendations, rules, and regulations where they apply. The firm does not receive compensation for any non-securities or non-investment banking related services. Neither the analyst nor the associate (if any), or any member of his/her household, serve as an officer, director or advisory board member of the subject company(ies). Cormark and its affiliates actively solicit investment banking business, including underwriting and advisory services, from its research coverage list. As a result, although uncertain, revenue from these activities may be received at any time. Cormark's research dissemination policies and procedures are available on its web-site.

RECOMMENDATION TERMINOLOGY

Cormark's recommendation terminology is as follows:

Top Pick	our best investment ideas, the greatest potential value appreciation
Buy	expected to outperform its peer group
Market Perform	expected to perform with its peer group
Reduce	expected to underperform its peer group

Our ratings may be followed by "(S)" which denotes that the investment is *speculative* and has a higher degree of risk associated with it.

Additionally, our target prices are set based on a 12-month investment horizon.

For Canadian Residents: This report has been approved by Cormark Securities Inc. ("CSI"), member IIROC and CIPF, which takes responsibility for this report and its dissemination in Canada. Canadian clients wishing to effect transactions in any security discussed should do so through a qualified salesperson of CSI. **For US Residents:** Cormark Securities (USA) Limited ("CUSA"), member FINRA and SIPC, accepts responsibility for this report and its dissemination in the United States. This report is intended for distribution in the United States only to certain institutional investors. US clients wishing to effect transactions in any security discussed should do so through a qualified salesperson of CUSA.

Every province in Canada, state in the US, and most countries throughout the world have their own laws regulating the types of securities and other investment products which may be offered to their residents, as well as the process for doing so. As a result, some of the securities discussed in this report may not be available to every interested investor. This report is not, and under no circumstances, should be construed as, a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to all clients and does not have regard to the particular circumstances or needs of any specific person who may read it. This report is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein.

The information and any statistical data contained herein have been obtained from sources believed to be reliable as of the date of publication, but the accuracy or completeness of the information is not guaranteed, nor in providing it does CSI or CUSA assume any responsibility or liability. All opinions expressed and data provided herein are subject to change without notice. The inventories of CSI or CUSA, its affiliated companies and the holdings of their respective directors, officers and companies with which they are associated may have a long or short position or deal as principal in the securities discussed herein. A CSI or CUSA company may have acted as underwriter or initial purchaser or placement agent for a private placement of any of the securities of any company mentioned in this report, may from time to time solicit from or perform financial advisory, or other services for such company. The securities mentioned in this report may not be suitable for all types of investors; their prices, value and/or the income they produce may fluctuate and/or be adversely affected by exchange rates.

No part of any report may be reproduced in any manner without prior written permission of CSI or CUSA.

A full list of our disclosure statements as well as our research dissemination policies and procedures can be found on our web-site at: www.cormark.com